Table 2 Status of methadone, buprenorphine, and extended-release naltrexone treatments for opioid addiction in the United States: Decrease and then increase in numbers in treatment 2015–2017 (SAMHSA, 2018).

TreatmentU.S. patients in treatment
201520162017
Methadone
maintenance
356,843345,443
(−11,400; −3.2%)
382,867
(+37,424; +10.8%)
Buprenorphine
maintenance
75,72361,486
(−14,237; −18.8%)
112,223
(+50,737; +82.5%)
Extended-release
naltrexone
703510,128
(+3093; +44.0%)
23,065
(+12,937; +128.7%)